Healthcare stocks were lower premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) easing 0.3%.
Hims & Hers Health (HIMS) stock was up more than 2% after the company said it has completed its acquisition of Eucalyptus, expanding its consumer health platform across Australia, Canada, Germany, and other international markets.
Heron Therapeutics (HRTX) shares were down 18% after the company said the US District Court for the District of Delaware has ruled that claims in two of its Cinvanti injectable emulsion patents are invalid.
Telix Pharmaceuticals (TLX) and United Imaging Healthcare North America signed a memorandum of understanding for a research collaboration in the US focused on integrated theranostics solutions. Telix Pharmaceuticals stock was down more than 2% pre-bell.